Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dainippon Of Japan To Establish U.S. Holding Company

This article was originally published in PharmAsia News

Executive Summary

Japan's Dainippon Sumitomo Pharma plans to establish a holding company in the United States to improve on the time it takes to get its drugs through the U.S. FDA approval process. The U.S. firm also is intended to serve as a sales base for its SM-13496 (lurasidone) drug for treating schizophrenia, which, although it is still in clinical trials, the company plans to have on the market as early as 2011. A Phase III trial of the drug has shown the drug to be far more effective than placebos in treating acute schizophrenia. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts